Purpose: Hypoxia is associated with aggressive tumour behaviour and can influence response to systemic therapy and radiotherapy. The prevalence of hypoxia in metastatic colorectal cancer is poorly understood, and the relationship of hypoxia to patient outcomes has not been clearly established. The aims of the study were to evaluate hypoxia in metastatic colorectal cancer with [F]Fluoromisonidazole ([F]FMISO PET) and correlate these findings with glycolytic metabolism ([F]FDG PET) and angiogenic blood biomarkers and patient outcomes.
Methods: Patients with metastatic colorectal cancer received routine staging investigations and both [F] FMISO PET and [F] FDG PET scans. Correlative blood specimens were also obtained at the time of the [F] FMISO PET scan. Patient follow-up was performed to establish progression-free survival.
Results: A total of 40 patients were recruited into the trial. [F]FMISO and [F]FDG PET scans showed a significant correlation of SUV (p = 0.003). A significant correlation of progression-free survival and [F] FMISO TNR (p = 0.02) and overall survival with [F]FMISO TNR (p = 0.003) and [F]FDG TGV (p = 0.02) was observed. Serum levels of osteopontin, but not VEGF, correlated with [F] FMISO and [F]FDG PET scan parameters.
Conclusion: [F]FMISO PET uptake in metastatic colorectal cancer significantly correlates with glycolytic metabolism and is predictive of progression-free and overall survival. These findings have implications for the assessment and treatment of metastatic colorectal cancer patients with novel therapies which affect tumour angiogenesis and hypoxia.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s00259-020-05074-5 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Genomic and cellular responses to aspirin in colonic organoids from African- and European-Americans.
Physiol Genomics
January 2025
Section of Gastroenterology, Hepatology and Nutrition, Department of Medicine, University of Chicago, Chicago, Illinois.
Aspirin (ASA) is a proven chemoprotective agent for colorectal cancer (CRC), though inter-individual responses and cellular mechanisms are not well characterized. Human organoids are ideal to study treatment responses across individuals. Here, colonic organoids from African-Americans (AA) and European-Americans (EA)were used to profile genomic and cellular ASA responses.
View Article and Find Full Text PDFDurable Remission After Targeted Therapy in Mutant Metastatic Colorectal Cancer: Case Report.
J Immunother Precis Oncol
February 2025
Department of Investigational Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX, USA.
BRAF mutation leads to constitutive activation of the MAPK pathway and is associated with the immune-activating molecular subtype of colorectal cancer. Targeted therapy for mutant metastatic colorectal cancer (CRC) has significantly improved outcomes for these patients when combined with anti-epithelial growth factor receptor (EGFR) therapy. However, most patients ultimately develop disease progression.
View Article and Find Full Text PDFImmunotherapy in colorectal cancer: Statuses and strategies.
Heliyon
January 2025
Shanghai Key Laboratory of Compound Chinese Medicines, The MOE Key Laboratory for Standardization of Chinese Medicines, Institute of Chinese Materia Medica, Shanghai University of Traditional Chinese Medicine, Shanghai, 201203, China.
Colorectal cancer (CRC) is widely recognized as the third most prevalent malignancy globally and the second leading cause of cancer-related mortality. Traditional treatment modalities for CRC, including surgery, chemotherapy, and radiotherapy, can be utilized either individually or in combination. However, these treatments frequently result in significant side effects due to their non-specificity and cytotoxicity affecting all cells.
View Article and Find Full Text PDFComparison of Different Machine Learning Models for Predicting Long-Term Overall Survival in Non-metastatic Colorectal Cancers.
Cureus
December 2024
Department of Medical Oncology, Ankara Bilkent City Hospital, Ankara, TUR.
Introduction: In recent years, machine learning (ML) methods have gained significant popularity among medical researchers interested in cancer. We aimed to test different (ML) models to predict both overall survival and survival at specific time points in patients with non-metastatic colorectal cancer (CRC).
Methods: The clinicopathological and treatment data of non-metastatic CRC patients with more than 10 years of follow-up at a single center were retrospectively reviewed.
Clinical Characteristics of and Treatment Pattern for EGFR-Amplified Colorectal Cancer.
Cancer Res Treat
January 2025
Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
Purpose: To compare clinicopathologic features and clinical outcomes of metastatic colorectal cancer (mCRC) based on EGFR amplification status.
Materials And Methods: Patients with mCRC who underwent next-generation sequencing using a targeted 244-gene panel from 2016 to 2021 were identified and screened for EGFR copy numbers. Cases with at least 5 copies were reviewed for tumor purity adjustment, and those with an adjusted copy number of ≥6 were defined as EGFR-amplified (EGFR amp+).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!